AlgiPharma AS
PrivateLast Round
Grant
Dec 20, 2021
Total Funding Raised
$23.57M
Company Overview
AlgiPharma AS operates in Healthcare & Life Sciences and is based in Norway. Its latest recorded funding round was a Grant round in December 2021.
AlgiPharma AS is a biopharmaceutical company that develops proprietary alginate technology for drug delivery platforms, drug conjugates, and therapeutic applications in areas such as cystic fibrosis, COPD, and infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AlgiPharma AS Comparables
Compare AlgiPharma AS with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Renovion, Inc. | 82% | |
| Enterprise Therapeutics | 80% | |
| Aer Therapeutics | 77% |
For institutional investors. Book with your work email.
AlgiPharma AS Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 20, 2021 | ||||
| Grant | Jan 15, 2018 | ||||
| Grant | Jan 15, 2018 | ||||
| Grant | Jan 15, 2018 | ||||
| Grant | Jan 15, 2018 | ||||
Grant | Jun 3, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
AlgiPharma AS Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovasjon Norge | Grant |
| European Union's Horizon 2020 | Grant |
| Cystic Fibrosis Foundation | Grant |
| Innovate UK | Grant |
| The Research Council of Norway | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 6, 2026
Monthly visitors increased 226% MoM, reaching 2.7K.
- Oct 30, 2025
Attended the Partnership Opportunities in Drug Delivery (PODD) conference 2025 in Boston.
For institutional investors. Book with your work email.
AlgiPharma AS Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AlgiPharma AS's valuation, stock price, and market status.
Is AlgiPharma AS a public or private company?
AlgiPharma AS is a private company.
What is the current stock price of AlgiPharma AS?
AlgiPharma AS is a private company, so its shares have no public market price. Caplight tracks AlgiPharma AS's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AlgiPharma AS worth (valuation)?
Valuation information for AlgiPharma AS is not publicly available.
Can I buy AlgiPharma AS stock?
AlgiPharma AS shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AlgiPharma AS's last funding round?
AlgiPharma AS's most recent funding round was Grant on December 20, 2021.
Who are the main investors in AlgiPharma AS?
Key investors in AlgiPharma AS include Innovasjon Norge, European Union's Horizon 2020, Cystic Fibrosis Foundation, Innovate UK, The Research Council of Norway.
Will AlgiPharma AS IPO soon?
No public IPO plans have been announced for AlgiPharma AS.
How can I track AlgiPharma AS secondary market activity?
Caplight tracks bids, offers, and trades in AlgiPharma AS's shares on secondary markets.